EYPT

EyePoint Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-05

Figures on this page computed 2026-11-08 12:40 UTC

Last close

0.39USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-05

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-093917
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-05
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-093917
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-05
The filing itself
-739.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-093917
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
-775.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-093917
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
0.07Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-093917
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-05
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.16 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.17x

2.82x

3.90x

0.93x

0.03x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-05

Sales1.17x
Its own average over 10 years, 26.8M.
Profit2.82x
Its own average over 10 years, -82.3M.
Free cash flow3.90x
Its own average over 10 years, -62.3M.
Debt0.93x
Its own average over 10 years, 24.6M.
Price0.03x
Its own average over 11 years, 13. Market data, 2026-11-04

Free cash flow is furthest from its own average, at 3.90 times.

Sales is 1.17 times its own 10-year average; Profit is 2.82 times its own 10-year average; Free cash flow is 3.90 times its own 10-year average; Debt is 0.93 times its own 10-year average; Price is 0.03 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-05

Sales against its own 10-year average1.17
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-093917
Reported in
USD
The filing itself
Profit against its own 10-year average2.82
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-093917
Reported in
USD
The filing itself
Free cash flow against its own 10-year average3.90
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-093917
Reported in
USD
The filing itself
Debt against its own 10-year average0.93
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-093917
Reported in
USD
The filing itself
Price against its own 11-year average0.03Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD